Article info
PDFHepatology
Original research
CXCR2 inhibition enables NASH-HCC immunotherapy
- Correspondence to Dr Derek A Mann, Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, Newcastle upon Tyne, UK; derek.mann{at}newcastle.ac.uk
Citation
CXCR2 inhibition enables NASH-HCC immunotherapy
Publication history
- Received October 5, 2021
- Accepted March 17, 2022
- First published April 27, 2022.
Online issue publication
May 04, 2023
Article Versions
- Previous version (4 May 2023).
- Previous version (4 May 2023).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.